- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06746831
Farmakologia izomerów metamfetaminy u ludzi
Podsumowanie izomerów metamfetaminy: rozpowszechnienie i farmakologia u ludzi
This study is being done to understand the metabolism and impairment profile of methamphetamine (meth). Meth exists as two chemical structures that are mirror images of each other: R-meth and S-meth. S-meth is a strong central nervous system stimulant and used to treat attention deficit disorder (ADD). R-meth is not a strong central nervous system stimulant and is available over-the-counter in nasal decongestant sprays.17 healthy participants will be enrolled for 3 study visits and on study for up to 12 weeks.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Double-blind crossover study design. Healthy volunteers will attend three study drug administration visits, at least 7 days apart, in which methamphetamine isomer pharmacology will be assessed following intravenous administration of (1) S-(+)-methamphetamine, (2) R(-)-methamphetamine, or (3) a (1:1) racemic mixture of R-(-)- and S-(+)-methamphetamine. The order of these interventions will be counterbalanced across participants. Serial blood samples will be drawn during each dosing visit and compared with concurrent dried blood spots from a finger stick, oral fluid collections, and pooled urine specimens.
Primary Objective
- Characterize the pharmacokinetics of acute S-(+)-methamphetamine administration.
- Characterize the pharmacokinetics of acute R-(-)-methamphetamine administration.
- Characterize the pharmacokinetics of acute racemic (1:1) R-(-)- and S-(+)-methamphetamine administration.
Secondary Objectives
- Assess for evidence of stereo-selective metabolic pathways.
- Assess for evidence of subjective, cognitive, or physiological effects from acute R-(-)-methamphetamine administration.
- Assess for evidence of more than additive effects when administering racemic methamphetamine.
Correlative Objectives
- Compare biological methamphetamine and metabolite concentrations in surveyed biological matrices (i.e., plasma, whole blood, oral fluid, dried capillary blood spots, and urine) over time.
- Compare cognitive and subjective effects of acute S-(+)-methamphetamine, R-(-)-methamphetamine, and racemic methamphetamine administration.
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 1
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Heather Barkholtz, PhD
- Numer telefonu: 608-890-1967
- E-mail: hbarkholtz@wisc.edu
Lokalizacje studiów
-
-
Wisconsin
-
Madison, Wisconsin, Stany Zjednoczone, 53705
- University of Wisconsin
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Good mental health as determined by self-reported responses to the Psychopathology Screener
- Absence of any major cardiac, neurologic, psychiatric, oncologic, endocrine, metabolic, renal, or hepatic disease as determined by self-reported responses to the Medical History Screener
- English-speaking (able to provide consent and complete questionnaires)
- Written Informed Consent
Exclusion Criteria:
- Any serious prior adverse response to sympathomimetic agents or amphetamine analogs
- History of or current substance use disorder as determined by self-reported responses to the Internalizing, Externalizing, and Substance Use Disorder Screener
- Pregnancy or lactation (pregnancy test, if needed)
- Use of medications that may impact cognition or metabolism (e.g., mood stabilizers, sedatives)
- Dependent on prohibited concomitant therapy that cannot be withheld for 48 hours prior to and during study visits.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Zadanie krzyżowe
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: S-Meth, R-Meth, Racemic Isomer
First visit: Administer S-Meth, then at least 7 days later Second visit: Administer R-Meth, then at least 7 days later Third visit: Administer (1:1) racemic methamphetamine |
15 mg
Inne nazwy:
15 mg
Inne nazwy:
15 mg R-Meth + 15 mg S-Meth |
|
Eksperymentalny: R-Meth, Racemic Isomer, S-Meth
First visit: Administer R-Meth, then at least 7 days later Second visit: Administer (1:1) racemic methamphetamine, then at least 7 days later Third visit: Administer S-Meth |
15 mg
Inne nazwy:
15 mg
Inne nazwy:
15 mg R-Meth + 15 mg S-Meth |
|
Eksperymentalny: Racemic Isomer, S-Meth, R-Meth
First visit: Administer (1:1) racemic methamphetamine, then at least 7 days later Second visit: Administer S-Meth, then at least 7 days later Third visit: Administer R-Meth |
15 mg
Inne nazwy:
15 mg
Inne nazwy:
15 mg R-Meth + 15 mg S-Meth |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Peak concentration (Cmax)
Ramy czasowe: pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48 hours
|
The pharmacokinetic analysis relies on observed drug and metabolite concentration measurements over time and across biological matrices (plasma, whole blood, dried capillary spots, oral fluid, urine) included in this study. |
pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48 hours
|
|
Area under the concentration versus time curve (AUC)
Ramy czasowe: pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48 hours
|
The pharmacokinetic analysis relies on observed drug and metabolite concentration measurements over time and across biological matrices (plasma, whole blood, dried capillary spots, oral fluid, urine) included in this study. |
pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48 hours
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Cognitive Effects: Divided Attention Task (DAT)
Ramy czasowe: Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
|
The DAT requires participants track a moving stimulus on a computer screen while simultaneously monitoring numbers located in the corners of the screen. Participants must respond to target numbers as they appear, and the task quantifies mean distance of the mouse cursor from the center of the target stimulus. |
Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
|
|
Cognitive Effects: Digital Symbol Substitution Task (DSST)
Ramy czasowe: Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
|
The DSST asks participants to recreate patterns of various shapes presented on a computer screen using the keyboard. The total number of correct patterns are recorded within 90 seconds. |
Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
|
|
Cognitive Effects: Paced Serial Addition Task (PASAT)
Ramy czasowe: Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
|
The PASAT has participants view a string of single-digit numbers and calculate the sum of the two most recently presented numbers. The total number of correct trials out of 90 will be recorded. |
Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
|
|
Subjective Effects: Drug Effect Questionnaire (DEQ)
Ramy czasowe: Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
|
Subjective current general effects will be measured by asking the participant to rate if they feel the drug effect, if they like/dislike the drug effect, if they feel high, and if they would like more of the drug. Effects will be measured on a scale from "not at all" anchored at 0 to "extremely" at 100. |
Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
|
|
Subjective Effects: Number of Participants Who Answer 'True' for Amphetamine-specific questions
Ramy czasowe: Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
|
Participants will be asked 11 amphetamine-specific questions including feelings of pleasantness, excitability, memory, emptiness, body tingling, weird feeling, patience, and mental sharpness. Results are measured as either "true" (experiencing the specific state) or "false" (not experiencing the specific state). Number of participants who answered 'True' is reported here |
Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: Heather K Barkholtz, PhD, University of Wisconsin, Madison
- Główny śledczy: David Leinweber, MD, University of Wisconsin, Madison
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Inne numery identyfikacyjne badania
- 2024-1164
- A523000 (Inny identyfikator: UW Madison)
- Protocol Version 2/12/25 (Inny identyfikator: UW Madison)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .